ONC

#399
BeOne Medicines Ltd. American Depositary Shares
312.7650 USD
+2.33%
Sektor:
Basis: USD
Gewinnwährung: USD
Tagesspanne
312.5700
313.2430
Jahresspanne
271.4701
385.2200
Tagesänderung
+2.33%
Monatliche Änderung
+9.32%
6 month change
-0.93%
Jahresänderung
-0.93%
Vorheriger Schlusskurs
305.6400
Eröffnung
312.5700
Bid
Ask
Tief
312.5700
High
313.2430
Volumen
36
Vollständige Grafik anzeigen

Financials

Übersicht Finanzbericht Statistik
Vierteljährlich Jährlich
  • Market Capitalization 34.6991 B
  • Employee 12 K
  • Founded 2010
  • CEO John Vincent OylerJohn Vincent Oyler
  • Website www.beonemedicines.com
  • Headquarter N/A
  • FIGI BBG00B6WF7T5
  • Industry Technology
Gesamtumsatz
Jahresüberschuss
Unverwässertes Ergebnis je Aktie (Unverwässertes EPS)
Gesamtverschuldung
Freier Cashflow
Zahlungsmittel und Zahlungsmitteläquivalente
Kurs-Gewinn-Verhältnis
1 599
Preis-Umsatz-Verhältnis
83.86

BeOne Medicines Ltd - American Depositary Shares

BeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment. Founded in 2010 by chief executive officer John V. Oyler and Xiaodong Wang, the company is headquartered in Cambridge, Massachusetts and has locations on six continents, in over 45 countries. BeOne has a large presence in the Chinese market. BeOne Medicines has developed several medicines, including tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton's tyrosine kinase inhibitor. On 14 November 2024 the company announced its intention to rebrand as BeOne Medicines. BeOne changed its stock ticker to ONC in January 2025 and redomiciled to Basel, Switzerland in May 2025.